These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32469893)

  • 21. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
    Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
    Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer.
    Low L; Mander A; McCann K; Dearnaley D; Tjelle T; Mathiesen I; Stevenson F; Ottensmeier CH
    Hum Gene Ther; 2009 Nov; 20(11):1269-78. PubMed ID: 19619001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation.
    Hooper JW; Moon JE; Paolino KM; Newcomer R; McLain DE; Josleyn M; Hannaman D; Schmaljohn C
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():110-7. PubMed ID: 24447183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.
    Luckay A; Sidhu MK; Kjeken R; Megati S; Chong SY; Roopchand V; Garcia-Hand D; Abdullah R; Braun R; Montefiori DC; Rosati M; Felber BK; Pavlakis GN; Mathiesen I; Israel ZR; Eldridge JH; Egan MA
    J Virol; 2007 May; 81(10):5257-69. PubMed ID: 17329330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Needle size for vaccination procedures in children and adolescents.
    Beirne PV; Hennessy S; Cadogan SL; Shiely F; Fitzgerald T; MacLeod F
    Cochrane Database Syst Rev; 2015 Jun; (6):CD010720. PubMed ID: 26086647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
    Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
    Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
    J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase IIb trial of
    Yang FQ; Rao GR; Wang GQ; Li YQ; Xie Y; Zhang ZQ; Deng CL; Mao Q; Li J; Zhao W; Wang MR; Han T; Chen SJ; Pan C; Tan DM; Shang J; Zhang MX; Zhang YX; Yang JM; Chen GM
    World J Gastroenterol; 2017 Jan; 23(2):306-317. PubMed ID: 28127204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.
    Chen WH; Neuzil KM; Boyce CR; Pasetti MF; Reymann MK; Martellet L; Hosken N; LaForce FM; Dhere RM; Pisal SS; Chaudhari A; Kulkarni PS; Borrow R; Findlow H; Brown V; McDonough ML; Dally L; Alderson MR
    Lancet Infect Dis; 2018 Oct; 18(10):1088-1096. PubMed ID: 30120069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle.
    Lin F; Shen X; McCoy JR; Mendoza JM; Yan J; Kemmerrer SV; Khan AS; Weiner DB; Broderick KE; Sardesai NY
    Vaccine; 2011 Sep; 29(39):6771-80. PubMed ID: 21199706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
    Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
    Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.
    Otten GR; Schaefer M; Doe B; Liu H; Megede JZ; Donnelly J; Rabussay D; Barnett S; Ulmer JB
    Vaccine; 2006 May; 24(21):4503-9. PubMed ID: 16181711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
    Rouphael NG; Paine M; Mosley R; Henry S; McAllister DV; Kalluri H; Pewin W; Frew PM; Yu T; Thornburg NJ; Kabbani S; Lai L; Vassilieva EV; Skountzou I; Compans RW; Mulligan MJ; Prausnitz MR;
    Lancet; 2017 Aug; 390(10095):649-658. PubMed ID: 28666680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques.
    Hirao LA; Wu L; Khan AS; Satishchandran A; Draghia-Akli R; Weiner DB
    Vaccine; 2008 Jan; 26(3):440-8. PubMed ID: 18082294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.
    McCoy JR; Mendoza JM; Spik KW; Badger C; Gomez AF; Schmaljohn CS; Sardesai NY; Broderick KE
    Hum Vaccin Immunother; 2014; 10(10):3039-47. PubMed ID: 25483486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation.
    Cristillo AD; Weiss D; Hudacik L; Restrepo S; Galmin L; Suschak J; Draghia-Akli R; Markham P; Pal R
    Biochem Biophys Res Commun; 2008 Feb; 366(1):29-35. PubMed ID: 18036339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
    Mehendale S; van Lunzen J; Clumeck N; Rockstroh J; Vets E; Johnson PR; Anklesaria P; Barin B; Boaz M; Kochhar S; Lehrman J; Schmidt C; Peeters M; Schwarze-Zander C; Kabamba K; Glaunsinger T; Sahay S; Thakar M; Paranjape R; Gilmour J; Excler JL; Fast P; Heald AE
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):873-80. PubMed ID: 18544020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
    Modjarrad K; Roberts CC; Mills KT; Castellano AR; Paolino K; Muthumani K; Reuschel EL; Robb ML; Racine T; Oh MD; Lamarre C; Zaidi FI; Boyer J; Kudchodkar SB; Jeong M; Darden JM; Park YK; Scott PT; Remigio C; Parikh AP; Wise MC; Patel A; Duperret EK; Kim KY; Choi H; White S; Bagarazzi M; May JM; Kane D; Lee H; Kobinger G; Michael NL; Weiner DB; Thomas SJ; Maslow JN
    Lancet Infect Dis; 2019 Sep; 19(9):1013-1022. PubMed ID: 31351922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.